{
  "symbol": "NEO",
  "company_name": "Neogenomics Inc",
  "ir_website": "https://ir.neogenomics.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.neogenomics.com/news-events/press-releases",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.neogenomics.com) Ignore\n\n[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Press Releases\n\nInvestor Relations News & Events Press Releases\n\nYear All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012\n\nCategory All Releases  Financial Releases \n\nNov 19, 2024 8:15am EST\n\n##  [ NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment ](https://ir.neogenomics.com/news-events/press-releases/detail/280/neogenomics-to-present-new-data-at-amp-2024-highlighting)\n\nNov 14, 2024 8:10am EST\n\n##  [ Felicia Williams Joins NeoGenomics Board of Directors ](https://ir.neogenomics.com/news-events/press-releases/detail/279/felicia-williams-joins-neogenomics-board-of-directors)\n\nNov 08, 2024 7:00am EST\n\n##  [ NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference ](https://ir.neogenomics.com/news-events/press-releases/detail/278/neogenomics-to-participate-in-the-piper-sandler-36th-annual)\n\nNov 05, 2024 7:00am EST\n\n##  [ NeoGenomics Reports Third Quarter 2024 Results ](https://ir.neogenomics.com/news-events/press-releases/detail/277/neogenomics-reports-third-quarter-2024-results)\n\nOct 22, 2024 8:10am EDT\n\n##  [ NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test ](https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo)\n\n[ rss_feed News RSS ](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "IR Calendar",
          "url": "https://ir.neogenomics.com/news-events/ir-calendar",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# IR Calendar\n\nInvestor Relations News & Events IR Calendar\n\n## Upcoming events\n\nDec 5, 2024 9:30 am EST\n\n##  [ Piper Sandler 36th Annual Healthcare Conference ](/news-events/ir-calendar/detail/20241205-piper-sandler-36th-annual-healthcare-conference)\n\n## Past events\n\nNov 19 – Nov 23, 2024\n\n##  Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo \n\nNov 5, 2024 8:30 am EST\n\n##  [ Third Quarter 2024 Financial Results Conference Call ](/news-events/ir-calendar/detail/20241105-third-quarter-2024-financial-results-conference-call)\n\nSep 24, 2024 8:30 am EST\n\n##  [ Business Update Call ](/news-events/ir-calendar/detail/20240924-business-update-call)\n\nSep 6, 2024 10:45 am EST\n\n##  [ Morgan Stanley 22nd Annual Global Healthcare Conference ](/news-events/ir-calendar/detail/20240906-morgan-stanley-22nd-annual-global-healthcare-conference)\n\nJul 29, 2024 4:30 pm EST\n\n##  [ Second Quarter 2024 Financial Results Conference Call ](/news-events/ir-calendar/detail/20240729-second-quarter-2024-financial-results-conference-call)\n\n[View all past events](/news-events/ir-calendar/past)\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "Presentations",
          "url": "https://ir.neogenomics.com/news-events/presentations",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Presentations\n\nInvestor Relations News & Events Presentations\n\n![](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/426/3243/pdf_thumbnail.jpg)\n\nNov 5, 2024\n\n##  [ NeoGenomics Investor Presentation – November 2024 ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/426/3243/pdf/NeoGenomics+3Q%2724+Earnings+Final+wAppendix+%2811.04.2024%29.pdf \"Opens in a new window\")\n\n[ rss_feed RSS ](/news-events/presentations/rss \"Opens in a new window\")\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "Literature",
          "url": "https://neogenomics.com/newsroom/literature?page=0",
          "content": "[ Skip to main content ](#main-content)\n\nContact Us\n\nFirst Name\n\nLast Name\n\nCompany\n\nEmail\n\nPhone\n\nCountry - None -AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d’IvoireDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorth KoreaNorth MacedoniaNorwayOmanOutlying OceaniaPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSamoaSan MarinoSarkSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaSão Tomé & PríncipeTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkmenistanTurks & Caicos IslandsTuvaluTürkiyeU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabweÅland Islands\n\nI am interested in - Select -ClinicalPharmaInformaticsResearch ProjectI am a patientOther\n\nComments\n\nSign me up for - None -Interested inNewsletterFirst Name\n\nReferral\n\nCampaign url\n\nLeave this field blank\n\n[ ![Home](/sites/default/files/2021-03/NEO_Logo_White.png) ](/)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ ](#)\n\n# Newsroom\n\nLiterature\n\nKeywords\n\nType - Any -AbstractCase studiesPosterPublicationWhite paper\n\nCategory - Any -Acute Myeloid LeukemiaAIALLBreast CancercfRNAColorectal CancerComputational ModelingCOVID-10ctDNACytogeneticsFISHGene FusionHead and Neck Squamous Cell CarcinomaHemeIHD1IHD2LeukemiaLiquid BiopsyLung CancerLymphomaMachine LearningMultiOmyxMultiple MyelomaMultiplex ImmunofluorescenceMyeloid NeoplasmsMyelomaNGSNTRKPD-L1RaDaRRNARNAScopeSpatialTumor mutational burdenVectra Polaris\n\nYear - Any -202420232022202120202019201820172016201520142013201220112010\n\nDeep phenotyping and spatial interrogation of the NSCLC tumor microenvironment using the fully validated Next Generation MultiOmyx™ Platform\n\nSITC 2024\n\n**\n\nPresented\n\nNov 9, 2024**\n\n**\n\nType\n\nPoster**\n\n[ Download ](/sites/default/files/literature/2024_SITC_Deep_phenotyping_and_spatial_interrogation_of_the_NSCLC_tumor_microenvironment_using_the_fully_validated_Next_Generation%20MultiOmyx_Platform.pdf)\n\nNEO | AML Express™ whitepaper\n\n**\n\nPresented\n\nNov 6, 2024**\n\n**\n\nType\n\nWhite paper**\n\n[ Download ](/sites/default/files/literature/AML_Express_White_Paper.PDF)\n\nDNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma\n\nOncoimmunology\n\n**\n\nPresented\n\nAug 5, 2024**\n\n**\n\nType\n\nAbstract**\n\n[ Read More ](https://www.tandfonline.com/doi/full/10.1080/2162402X.2024.2384667)\n\nTargeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy\n\nJournal for ImmunoTherapy of Cancer\n\n**\n\nPresented\n\nJul 10, 2024**\n\n**\n\nType\n\nPublication**\n\n[ Learn More ](https://jitc.bmj.com/content/jitc/12/7/e009368.full.pdf)\n\nComparative analysis of actionable gene reporting in targeted panels versus comprehensive NGS testing for solid tumor samples\n\nASCO 2024\n\n**\n\nPresented\n\nJun 3, 2024**\n\n**\n\nType\n\nPoster**\n\n[ Download ](/sites/default/files/literature/ASCO_2024_Comparative_analysis_of_actionable_gene_reporting_in_targeted_panels_versus_comprehensive_NGS_testing_for_solid_tumor_samples.pdf)\n\nHighly frequent gene mutations and co-occurring genes analysis in colorectal cancer (CRC)\n\nAACR 2024\n\n**\n\nPresented\n\nApr 9, 2024**\n\n**\n\nType\n\nPoster**\n\n[ Download ](/sites/default/files/literature/AACR-2024-Highly-frequent-gene-mutations-and-co-occurring-genes-analysis-in-colorectal-cancer.pdf)\n\nImproved Spatial Biology Analysis of the Tumor Microenvironment with the Next Generation of the MultiOmyx™ Platform\n\nAACR 2024\n\n**\n\nPresented\n\nApr 9, 2024**\n\n**\n\nType\n\nPoster**\n\n[ Download ](/sites/default/files/literature/AACR-2024-Improved-Spatial-Biology-Analysis-of-the-Tumor-Microenvironment-with-the-Next-Generation-of-the-MultiOmyx-Platform.pdf)\n\nOptimization and Evaluation of an FFPE Dual Extraction Protocol for Next Generation Sequencing Applications\n\nAACR 2024\n\n**\n\nPresented\n\nApr 9, 2024**\n\n**\n\nType\n\nPoster**\n\n[ Download ](/sites/default/files/literature/AACR-2024-Optimization-and-Evaluation-of-an-FFPE-Dual-Extraction-Protocol-for-Next-Generation-Sequencing-Applications.pdf)\n\n#### Contact Us To Get Started!\n\nWork with us – your premier oncology partner – to optimize cancer care for patients\n\n[ Learn More ](/contact-us)\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\n![](https://px.adentifi.com/Pixels?a_id=21499;p_url=https%3A%2F%2Fneogenomics.com%2Fnewsroom%2Fliterature%3Fpage%3D0;uq=9631227183319.676)![](https://t.co/i/adsct?bci=3&dv=Asia%2FCalcutta%26en-US%26Google%20Inc.%26Win32%26255%261920%261080%268%2624%261920%261080%260%26na&eci=2&event_id=13ac2ae5-88c0-4fac-8762-3364d208c068&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=eb0fd71a-250f-4559-b05c-095c9fae46a3&tw_document_href=https%3A%2F%2Fneogenomics.com%2Fnewsroom%2Fliterature%3Fpage%3D0&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o77qr&type=javascript&version=2.3.31)![](https://analytics.twitter.com/i/adsct?bci=3&dv=Asia%2FCalcutta%26en-US%26Google%20Inc.%26Win32%26255%261920%261080%268%2624%261920%261080%260%26na&eci=2&event_id=13ac2ae5-88c0-4fac-8762-3364d208c068&events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&integration=advertiser&p_id=Twitter&p_user_id=0&pl_id=eb0fd71a-250f-4559-b05c-095c9fae46a3&tw_document_href=https%3A%2F%2Fneogenomics.com%2Fnewsroom%2Fliterature%3Fpage%3D0&tw_iframe_status=0&tw_order_quantity=0&tw_sale_amount=0&txn_id=o77qr&type=javascript&version=2.3.31)\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://ir.neogenomics.com/news-events/email-alerts",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Email Alerts\n\nInvestor Relations News & Events Email Alerts\n\nPlease fill out the form below to receive company press releases via email when they occur.\n\nDo you want to load external content supplied by hCaptcha?\n\nYes\n\n*Required Fields\n\nFirst Name:*\n\nLast Name:*\n\nEmail:*\n\nContact Type: Individual Investor  Analyst  Broker/Investment Advisor  Portfolio Manager  Banker/Financing Source  Press/Media  Consultant  Employee  Customer/Client  Student  Other \n\n## Choose Notifications\n\n### Company Information\n\n  * All Press Releases\n\n\n\n### SEC Filings\n\n  * All SEC Filings\n    * Annual & Quarterly Reports\n    * Current Reports\n    * Insider Transactions\n    * Proxy Information\n\n\n\nThis site is protected by hCaptcha and its [Privacy Policy](https://hcaptcha.com/privacy) and [Terms of Service](https://hcaptcha.com/terms) apply. \n\nSubmit\n\nWe respect your privacy. We do not sell, rent, or loan any information to any third party. Any information you give us is held with the utmost care and security, and will be used only in ways to which you have consented. \n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        }
      ]
    },
    {
      "section_name": "ESG Reports",
      "links": [
        {
          "title": "NeoGenomics Releases Inaugural ESG Report",
          "url": "https://ir.neogenomics.com/news-events/press-releases/detail/262/neogenomics-releases-inaugural-environmental-social-and",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.neogenomics.com) Ignore\n\n[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\nPress Releases\n\nInvestor Relations News & Events Press Releases\n\n# NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report\n\nMarch 20, 2024 7:00am EDT  [ Download as PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2024-03-20_NeoGenomics_Releases_Inaugural_Environmental_262.pdf \"PDF: NeoGenomics Releases Inaugural Environmental, Social, and Governance \\(ESG\\) Report\")\n\nFT. MYERS, Fla.--(BUSINESS WIRE)-- **NeoGenomics, Inc. (NASDAQ: NEO),** a leading oncology testing services company, today released its [2023 Environmental, Social, and Governance (ESG) Report](https://ir.neogenomics.com/corporate-governance/esg-report) highlighting progress toward building a more sustainable, diverse, and equitable company that delivers exceptional customer experience and advanced testing options. This inaugural report details the performance and management of NeoGenomics’ commitment to its core values of quality, integrity, accountability, teamwork, and innovation. \n\n“Releasing our first ESG report marks an important milestone in NeoGenomics’ growth and evolution,” said Chris Smith, CEO at NeoGenomics. “Through these efforts, we have established foundational pillars to serve as a beacon for building a sustainable company that provides exceptional customer experience and advanced testing options.” \n\nThe 2023 ESG Report measures progress on key sustainability focus areas, including Customer Privacy, Data and Cybersecurity, Recruitment, Development and Retention, Business Ethics, Product Quality and Safety, Legal and Regulatory Environment, and Environmental Stewardship. \n\nHighlights of the report include: \n\n  * **Progressing diversity, equity, inclusion, and belonging efforts.** NeoGenomics continues its commitment to maintaining a supportive workplace, which includes investing in ongoing opportunities for teammate development in a diverse and inclusive environment. At the end of 2023, women comprised 59.9% of the global workforce, 53.5% of the US workforce was ethnically diverse, and 73% of employees had been impacted by cancer. \n  * **Pursuing environmental stewardship.** In 2023, NeoGenomics recycled 310 tons of waste from its labs in Fort Myers, FL, and Aliso Viejo, CA. The NeoGreen program allowed for 24.5% of all waste to be recycled. \n  * **Protecting stakeholders with strong corporate governance.** NeoGenomics expanded its Board of Directors by appointing three new independent board members with over 50 years of executive experience in digital technologies, global marketing, and molecular diagnostics. \n  * **Promoting teammate growth and engagement**. NeoGenomics’ 2023 Employee Engagement Survey showed net improvements in Employee Happiness and Employee Engagement and decreased voluntary employee turnover to 13%. \n\n\n\n“While completing our research and aggregating the data for the report, it quickly became apparent that ESG principles have been at the core of our work for some time now,” added Smith. “I am more optimistic than ever about what lies ahead for NeoGenomics. Our 2024 plans and pipeline will move us closer to serving 1 million patients annually by 2028.” \n\n**About NeoGenomics, Inc.**\n\nNeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company's Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development. \n\nHeadquartered in Fort Myers, FL, NeoGenomics operates CAP-accredited and CLIA-certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP-accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. \n\nView source version on businesswire.com: <https://www.businesswire.com/news/home/20240320977067/en/>\n\n**Investor Contact** Kendra Sweeney Vice President, Investor Relations and ESG kendra.sweeney@neogenomics.com\n\n**Media Contact** Andrea Sampson President/CEO, Sampson Public Relations Group asampson@sampsonprgroup.com\n\nSource: NeoGenomics, Inc.\n\nReleased March 20, 2024\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "2023 NEO ESG Report",
          "url": "https://d1io3yog0oux5.cloudfront.net/_a06b63c5b24343ab3e90e2842b98065d/neogenomics/files/2023_NEO_ESG_Report_vFinal.pdf",
          "content": "Error extracting PDF content: bytes must be in range(0, 256)"
        }
      ]
    },
    {
      "section_name": "Financial Information",
      "links": [
        {
          "title": "Financial Results",
          "url": "https://ir.neogenomics.com/financial-information/financial-results",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Financial Results\n\nInvestor Relations Financial Information Financial Results\n\n## 2024\n\n### Q3 2024\n\nQuarter Ended Sep 30, 2024\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/277/neogenomics-reports-third-quarter-2024-results) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2024-11-05_NeoGenomics_Reports_Third_Quarter_2024_277.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/51435 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3241/presentation/NeoGenomics+3Q%2724+Earnings+Final+wAppendix+%2811.04.2024%29.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-24-000157/neo-20240930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157-xbrl.zip \"Opens in a new window\")\n\n### Q2 2024\n\nQuarter Ended Jun 30, 2024\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/270/neogenomics-reports-second-quarter-2024-results) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2024-07-29_NeoGenomics_Reports_Second_Quarter_2024_270.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/50847 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3232/presentation/NeoGenomics+2Q%2724+Earnings+Slides_v.7.29.24_FINAL.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-24-000109/neo-20240630.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-24-000109/0001077183-24-000109.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-24-000109/0001077183-24-000109-xbrl.zip \"Opens in a new window\")\n\n### Q1 2024\n\nQuarter Ended Mar 31, 2024\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/266/neogenomics-reports-first-quarter-2024-results) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2024-04-30_NeoGenomics_Reports_First_Quarter_2024_266.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/50374 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3229/presentation/NeoGenomics+1Q%2724+Earnings+Slides_vFINAL.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-24-000054/neo-20240331.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-24-000054/0001077183-24-000054.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-24-000054/0001077183-24-000054-xbrl.zip \"Opens in a new window\")\n\n## 2023\n\n### FY 2023\n\nFiscal Year Ended Dec 31, 2023\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/260/neogenomics-reports-fourth-quarter-and-full-year-2023) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2024-02-20_NeoGenomics_Reports_Fourth_Quarter_and_Full_Year_260.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/49745 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3180/presentation/NeoGenomics+4Q+and+FY23+Earnings+Slides_vFINAL_02.21.24.pdf \"Opens in a new window\")\n\n[Webcast Audio Description](#webcast_audio_description_0d629cc01bddadd20a880d18cfba3b044152cc5fed656c16c8189456c5884f35) [Transcript](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3180/webcast_transcript/NeoGenomics+FY2023+Earnings+Call.pdf \"Opens in a new window\")\n\nSorry, your browser doesn't support embedded video. \n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001077183-24-000011/neo-20231231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-24-000011/0001077183-24-000011.pdf \"Opens in a new window\")\n\n### Q3 2023\n\nQuarter Ended Sep 30, 2023\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/253/neogenomics-reports-third-quarter-2023-results) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2023-11-06_NeoGenomics_Reports_Third_Quarter_2023_253.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/49230 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3169/presentation/NeoGenomics+3Q23+Earnings+Slides_vFINAL.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-23-000138/neo-20230930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-23-000138/0001077183-23-000138.pdf \"Opens in a new window\")\n\n### Q2 2023\n\nQuarter Ended Jun 30, 2023\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/250/neogenomics-reports-second-quarter-2023-results) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2023-08-08_NeoGenomics_Reports_Second_Quarter_2023_250.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/48629 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3159/presentation/NeoGenomics2Q23EarningsSlides_vFINAL_16109114845.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-23-000103/neo-20230630.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-23-000103/0001077183-23-000103.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-23-000103/0001077183-23-000103-xbrl.zip \"Opens in a new window\")\n\n### Q1 2023\n\nQuarter Ended Mar 31, 2023\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/242/neogenomics-reports-first-quarter-2023-results) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2023-05-08_NeoGenomics_Reports_First_Quarter_2023_242.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/48169 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3139/presentation/NeoGenomics+1Q23+Earnings+Slides+_v11.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-23-000042/neo-20230331.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-23-000042/0001077183-23-000042.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-23-000042/0001077183-23-000042-xbrl.zip \"Opens in a new window\")\n\n## 2022\n\n### FY 2022\n\nFiscal Year Ended Dec 31, 2022\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/233/neogenomics-reports-fourth-quarter-and-full-year-2022) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2023-02-23_NeoGenomics_Reports_Fourth_Quarter_and_Full_Year_233.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/47529 \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001077183-23-000023/neo-20221231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-23-000023/0001077183-23-000023.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-23-000023/0001077183-23-000023-xbrl.zip \"Opens in a new window\")\n\n### Q3 2022\n\nQuarter Ended Sep 30, 2022\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/226/neogenomics-reports-third-quarter-2022-results) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2022-11-08_NeoGenomics_Reports_Third_Quarter_2022_226.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/46818 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3006/presentation/NEO+Investor+Powerpoint+Q3+2022+Earnings.pdf \"Opens in a new window\")\n\n[Webcast Audio Description](#webcast_audio_description_df25add2f4a4b0b5545ff6ba03b731e060d90215af5f6e4d069ec4689ca34c09) [Transcript](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3006/webcast_transcript/NeoGenomics+3Q22+Earnings+Call_merged.pdf \"Opens in a new window\")\n\nSorry, your browser doesn't support embedded video. \n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-22-000173/neo-20220930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-22-000173/0001077183-22-000173.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-22-000173/0001077183-22-000173-xbrl.zip \"Opens in a new window\")\n\n### Q2 2022\n\nQuarter Ended Jun 30, 2022\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/218/neogenomics-reports-revenue-of-125-million-in-the-second) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2022-08-09_NeoGenomics_Reports_Revenue_of_125_Million_in_the__218.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/46116 \"Opens in a new window\") [Transcript](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3005/webcast_transcript/NEO-Q2-2022-46116.stamped_doc.pdf \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3005/presentation/Q2%2722_Investor_Presentation.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3005/managements_prepared_remarks/Q222_Earnings_Prepared_Remarks_FINAL.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-22-000135/neo-20220630.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-22-000135/0001077183-22-000135.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-22-000135/0001077183-22-000135-xbrl.zip \"Opens in a new window\")\n\n### Q1 2022\n\nQuarter Ended Mar 31, 2022\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/208/neogenomics-reports-revenue-of-117-million-in-the-first) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2022-04-27_NeoGenomics_Reports_Revenue_of_117_Million_in_the__208.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/45198 \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3004/managements_prepared_remarks/Quarter_1_2022_Prepared_Remarks.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-22-000081/neo-20220331.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-22-000081/0001077183-22-000081.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-22-000081/0001077183-22-000081-xbrl.zip \"Opens in a new window\")\n\n## 2021\n\n### FY 2021\n\nFiscal Year Ended Dec 31, 2021\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/200/neogenomics-reports-full-year-revenue-of-484-million-and) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2022-02-23_NeoGenomics_Reports_Full_Year_Revenue_of_484_200.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Audio ](https://www.webcaster4.com/Webcast/Page/1219/44519 \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3003/presentation/NEO_Investor_Powerpoint_Q4_Earnings_FINAL.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3003/managements_prepared_remarks/Quarter_4_2021_Earnings_Script_FINAL_For_Website.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001077183-22-000017/neo-20211231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-22-000017/0001077183-22-000017.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-22-000017/0001077183-22-000017-xbrl.zip \"Opens in a new window\")\n\n### Q3 2021\n\nQuarter Ended Sep 30, 2021\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/189/neogenomics-reports-revenue-of-121-million-in-the-third) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2021-11-04_NeoGenomics_Reports_Revenue_of_121_Million_in_the__189.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3002/managements_prepared_remarks/Q3_2021_Earnings_Call_Script_FINAL.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-21-000237/neo-20210930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-21-000237/0001077183-21-000237.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-21-000237/0001077183-21-000237-xbrl.zip \"Opens in a new window\")\n\n### Q2 2021\n\nQuarter Ended Jun 30, 2021\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/182/neogenomics-reports-40-revenue-growth-to-122-million-in) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2021-08-06_NeoGenomics_Reports_40_Revenue_Growth_to_122_182.pdf \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3001/presentation/NEO_Investor_Powerpoint_Q2_Earnings_-_FINAL.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3001/managements_prepared_remarks/Q2_2021_Earnings_Call_Prepared_Remarks_-_Final.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-21-000205/neo-20210630.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-21-000205/0001077183-21-000205.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-21-000205/0001077183-21-000205-xbrl.zip \"Opens in a new window\")\n\n### Q1 2021\n\nQuarter Ended Mar 31, 2021\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/177/neogenomics-reports-9-revenue-growth-to-116-million-in) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2021-05-05_NeoGenomics_Reports_9_Revenue_Growth_to_116_177.pdf \"Opens in a new window\")\n\n[ Presentation PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3000/presentation/NEO_Investor_Powerpoint_Inivata_Public_Call.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/3000/managements_prepared_remarks/Q1_2021_Earnings_Call_Prepared_Remarks.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-21-000128/neo-20210331.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-21-000128/0001077183-21-000128.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-21-000128/0001077183-21-000128-xbrl.zip \"Opens in a new window\")\n\n## 2020\n\n### FY 2020\n\nFiscal Year Ended Dec 31, 2020\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/168/neogenomics-reports-18-revenue-growth-to-126-million-in) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2021-02-24_NeoGenomics_Reports_18_Revenue_Growth_to_126_168.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2999/managements_prepared_remarks/Quarter_4_2020_Earnings_Prepared_Remarks_For_Website.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001077183-21-000064/neo-20201231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-21-000064/0001077183-21-000064.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-21-000064/0001077183-21-000064-xbrl.zip \"Opens in a new window\")\n\n### Q3 2020\n\nQuarter Ended Sep 30, 2020\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/157/neogenomics-reports-revenue-growth-of-20-to-record-125) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2020-10-27_NeoGenomics_Reports_Revenue_Growth_of_20_to_157.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2998/managements_prepared_remarks/Q3_Earnings_Prepared_Remarks_-_Website.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-20-000206/neo-20200930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-20-000206/0001077183-20-000206.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-20-000206/0001077183-20-000206-xbrl.zip \"Opens in a new window\")\n\n### Q2 2020\n\nQuarter Ended Jun 30, 2020\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/153/neogenomics-reports-revenue-of-87-million-in-the-second) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2020-07-28_NeoGenomics_Reports_Revenue_of_87_Million_in_the_153.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2997/managements_prepared_remarks/Q2_Earnings_Script_Website.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-20-000166/neo-20200630.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-20-000166/0001077183-20-000166.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-20-000166/0001077183-20-000166-xbrl.zip \"Opens in a new window\")\n\n### Q1 2020\n\nQuarter Ended Mar 31, 2020\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/141/neogenomics-reports-11-revenue-growth-to-106-million-in) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2020-04-28_NeoGenomics_Reports_11_Revenue_Growth_to_106_141.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2996/managements_prepared_remarks/Q1_Earnings_Script_Final_for_Website_-_FINAL.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-20-000063/neo-20200331.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-20-000063/0001077183-20-000063.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-20-000063/0001077183-20-000063-xbrl.zip \"Opens in a new window\")\n\n## 2019\n\n### FY 2019\n\nFiscal Year Ended Dec 31, 2019\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/135/neogenomics-reports-40-revenue-growth-to-107-million-in) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2020-02-27_NeoGenomics_Reports_40_Revenue_Growth_to_107_135.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Transcript ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2995/webcast_transcript/Q4_2019_Earnings_Script_.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001077183-20-000022/neo-20191231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-20-000022/0001077183-20-000022.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-20-000022/0001077183-20-000022-xbrl.zip \"Opens in a new window\")\n\n### Q3 2019\n\nQuarter Ended Sep 30, 2019\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/130/neogenomics-reports-51-revenue-growth-to-105-million-in) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2019-10-29_NeoGenomics_Reports_51_Revenue_Growth_to_105_130.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Transcript ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2994/webcast_transcript/Q3_Earnings_Script_-_Website.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-19-000206/neo-20190930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-19-000206/0001077183-19-000206.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-19-000206/0001077183-19-000206-xbrl.zip \"Opens in a new window\")\n\n### Q2 2019\n\nQuarter Ended Jun 30, 2019\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/124/neogenomics-reports-50-revenue-growth-to-record-102) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2019-07-30_NeoGenomics_Reports_50_Revenue_Growth_to_Record_124.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Transcript ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2993/webcast_transcript/Q2_Earnings_Script_final_post_call.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-19-000136/neo-20190630.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-19-000136/0001077183-19-000136.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-19-000136/0001077183-19-000136-xbrl.zip \"Opens in a new window\")\n\n### Q1 2019\n\nQuarter Ended Mar 31, 2019\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/115/neogenomics-reports-51-revenue-growth-to-record-96) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2019-04-30_NeoGenomics_Reports_51_Revenue_Growth_to_Record_115.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Transcript ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2992/webcast_transcript/Q1_Earnings_Script_-_4.30.2019_Post_Call_edit.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-19-000066/neo-20190331.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-19-000066/0001077183-19-000066.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-19-000066/0001077183-19-000066-xbrl.zip \"Opens in a new window\")\n\n## 2018\n\n### FY 2018\n\nFiscal Year Ended Dec 31, 2018\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/110/neogenomics-reports-record-revenue-of-76-million-with-17) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2019-02-19_NeoGenomics_Reports_Record_Revenue_of_76_Million_110.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2991/managements_prepared_remarks/NeoGenomics_Q4_Earnings_Call_Prepared_Remarks.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001077183-19-000008/neo-20181231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-19-000008/0001077183-19-000008.pdf \"Opens in a new window\")\n\n[ 10-K/A HTML ](/sec-filings/all-sec-filings/content/0001077183-19-000064/neo1231201810-kanoxbrl.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-19-000064/0001077183-19-000064.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-19-000008/0001077183-19-000008-xbrl.zip \"Opens in a new window\")\n\n### Q3 2018\n\nQuarter Ended Sep 30, 2018\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/103/neogenomics-reports-17-revenue-growth-to-record-69-million) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2018-10-30_NeoGenomics_Reports_17_Revenue_Growth_to_Record_103.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2990/managements_prepared_remarks/2018_Q3_Prepared_Remarks.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-18-000105/neo-09302018x10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-18-000105/0001077183-18-000105.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-18-000105/0001077183-18-000105-xbrl.zip \"Opens in a new window\")\n\n### Q2 2018\n\nQuarter Ended Jun 30, 2018\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/96/neogenomics-reports-record-revenue-of-67-7-million-with) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2018-07-24_NeoGenomics_Reports_Record_Revenue_of_67_7_96.pdf \"Opens in a new window\")\n\n[ Earnings Webcast Transcript ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2989/webcast_transcript/2018_Q2_Earnings_Call_Script_7_24_18.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-18-000075/neo-06302018x10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-18-000075/0001077183-18-000075.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-18-000075/0001077183-18-000075-xbrl.zip \"Opens in a new window\")\n\n### Q1 2018\n\nQuarter Ended Mar 31, 2018\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/91/neogenomics-reports-revenue-of-63-4-million-net-income-of) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2018-05-01_NeoGenomics_Reports_Revenue_of_63_4_Million_Net_91.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2988/managements_prepared_remarks/Q1_2018_Earnings_Call_Prepared_Remarks.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001077183-18-000017/neo-033118x10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001077183-18-000017/0001077183-18-000017.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001077183-18-000017/0001077183-18-000017-xbrl.zip \"Opens in a new window\")\n\n## 2017\n\n### FY 2017\n\nFiscal Year Ended Dec 31, 2017\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/88/neogenomics-reports-revenue-of-67-8-million-on-18-7) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2018-02-21_NeoGenomics_Reports_Revenue_of_67_8_Million_on_18__88.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2987/managements_prepared_remarks/2017_Q4_Earnings_Call_Script_v11.1_-_Final_for_Upload_-_Corrected.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001564590-18-005479/neo-10k_20171231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-18-005479/0001564590-18-005479.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-18-005479/0001564590-18-005479-xbrl.zip \"Opens in a new window\")\n\n### Q3 2017\n\nQuarter Ended Sep 30, 2017\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/83/neogenomics-reports-revenue-of-63-1-million-on-17-volume) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2017-10-25_NeoGenomics_Reports_Revenue_of_63_1_Million_on_17__83.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2986/managements_prepared_remarks/2017_Q3_Earnings_Call_Script_v10_-_Final_Post_Call_%28as_uploaded_to_Website%29.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001564590-17-023566/neo-10q_20170930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-17-023566/0001564590-17-023566.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-17-023566/0001564590-17-023566-xbrl.zip \"Opens in a new window\")\n\n### Q2 2017\n\nQuarter Ended Jun 30, 2017\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/78/neogenomics-reports-record-revenue-of-66-1-million-on-16) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2017-07-25_NeoGenomics_Reports_Record_Revenue_of_66_1_78.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2985/managements_prepared_remarks/2017_Q2_Earnings_Call_Script_v11_FINAL_%28As_Used_on_Earnings_Call_without_Q%26A%29.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001564590-17-015930/neo-10q_20170630.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-17-015930/0001564590-17-015930.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-17-015930/0001564590-17-015930-xbrl.zip \"Opens in a new window\")\n\n### Q1 2017\n\nQuarter Ended Mar 31, 2017\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/74/neogenomics-reports-15-volume-growth-and-10-reduction-in) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2017-04-26_NeoGenomics_Reports_15_Volume_Growth_and_10_74.pdf \"Opens in a new window\")\n\n[ Management's Prepared Remarks PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2984/managements_prepared_remarks/2017_Q1_Earnings_Call_Script_v10_-_FINAL_Post_-_Call_%28Without_Anticipated_QA%29.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001564590-17-009543/neo-10q_20170331.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-17-009543/0001564590-17-009543.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-17-009543/0001564590-17-009543-xbrl.zip \"Opens in a new window\")\n\n## 2016\n\n### FY 2016\n\nFiscal Year Ended Dec 31, 2016\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/70/neogenomics-reports-122-revenue-growth-to-60-5-million) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2017-02-22_NeoGenomics_Reports_122_Revenue_Growth_to_60_5_70.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001564590-17-004158/neo-10k_20161231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-17-004158/0001564590-17-004158.pdf \"Opens in a new window\")\n\n[ 10-K/A HTML ](/sec-filings/all-sec-filings/content/0001564590-17-023552/neo-10ka_20161231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-17-023552/0001564590-17-023552.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-17-004158/0001564590-17-004158-xbrl.zip \"Opens in a new window\")\n\n### Q3 2016\n\nQuarter Ended Sep 30, 2016\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/67/neogenomics-reports-142-revenue-growth-to-60-8-million) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2016-10-26_NeoGenomics_Reports_142_Revenue_Growth_to_60_8_67.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001564590-16-027730/neo-10q_20160930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-16-027730/0001564590-16-027730.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-16-027730/0001564590-16-027730-xbrl.zip \"Opens in a new window\")\n\n### Q2 2016\n\nQuarter Ended Jun 30, 2016\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/65/neogenomics-reports-159-revenue-growth-to-63-1-million) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2016-07-26_NeoGenomics_Reports_159_Revenue_Growth_to_63_1_65.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001564590-16-023004/neo-10q_20160630.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-16-023004/0001564590-16-023004.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-16-023004/0001564590-16-023004-xbrl.zip \"Opens in a new window\")\n\n### Q1 2016\n\nQuarter Ended Mar 31, 2016\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/63/neogenomics-reports-159-revenue-growth-to-59-7-million) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2016-04-27_NeoGenomics_Reports_159_Revenue_growth_to_59_7_63.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001564590-16-018998/neo-10q_20160331.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-16-018998/0001564590-16-018998.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-16-018998/0001564590-16-018998-xbrl.zip \"Opens in a new window\")\n\n## 2015\n\n### FY 2015\n\nFiscal Year Ended Dec 31, 2015\n\nAnnual Report [ ![Year End Results](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2979/annual_report_resized.jpg) ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2979/annual_report/NEO_FINAL_PROOF_ANNUAL_REPORT.pdf \"Opens in a new window\")\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/61/neogenomics-reports-record-revenue-of-27-2-million-and) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2016-03-01_NeoGenomics_Reports_Record_Revenue_of_27_2_61.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001564590-16-014868/neo-10k_20151231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-16-014868/0001564590-16-014868.pdf \"Opens in a new window\")\n\n[ 10-K/A HTML ](/sec-filings/all-sec-filings/content/0001564590-16-016328/neo-10ka_20151231.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-16-016328/0001564590-16-016328.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-16-016328/0001564590-16-016328-xbrl.zip \"Opens in a new window\")\n\n[ Annual Report PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2979/annual_report/NEO_FINAL_PROOF_ANNUAL_REPORT.pdf \"Opens in a new window\")\n\n### Q3 2015\n\nQuarter Ended Sep 30, 2015\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/57/neogenomics-reports-revenue-of-25-1-million-and-record) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2015-10-29_NeoGenomics_Reports_Revenue_of_25_1_Million_and_57.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001564590-15-009957/neo-10q_20150930.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001564590-15-009957/0001564590-15-009957.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001564590-15-009957/0001564590-15-009957-xbrl.zip \"Opens in a new window\")\n\n### Q2 2015\n\nQuarter Ended Jun 30, 2015\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/51/neogenomics-reports-18-revenue-growth-and-strong-gains-in) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2015-07-23_NeoGenomics_Reports_18_Revenue_Growth_and_Strong_51.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-15-272903/d935395d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-15-272903/0001193125-15-272903.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-15-272903/0001193125-15-272903-xbrl.zip \"Opens in a new window\")\n\n### Q1 2015\n\nQuarter Ended Mar 31, 2015\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/44/neogenomics-reports-27-revenue-growth-driven-by-strong) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2015-04-28_NeoGenomics_Reports_27_Revenue_Growth_Driven_by_44.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-15-181991/d902771d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-15-181991/0001193125-15-181991.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-15-181991/0001193125-15-181991-xbrl.zip \"Opens in a new window\")\n\n## 2014\n\n### FY 2014\n\nFiscal Year Ended Dec 31, 2014\n\nAnnual Report [ ![Year End Results](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2975/annual_report_resized.jpg) ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2975/annual_report/neogenomics_2014_Annual_Report_Final.pdf \"Opens in a new window\")\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/41/neogenomics-reports-record-revenue-of-25-0-million) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2015-02-24_NeoGenomics_Reports_Record_Revenue_of_25_0_41.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001193125-15-075318/d832983d10k.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-15-075318/0001193125-15-075318.pdf \"Opens in a new window\")\n\n[ 10-K/A HTML ](/sec-filings/all-sec-filings/content/0001193125-15-161819/d918967d10ka.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-15-161819/0001193125-15-161819.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-15-075318/0001193125-15-075318-xbrl.zip \"Opens in a new window\")\n\n[ Annual Report PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2975/annual_report/neogenomics_2014_Annual_Report_Final.pdf \"Opens in a new window\")\n\n### Q3 2014\n\nQuarter Ended Sep 30, 2014\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/37/neogenomics-reports-38-increase-in-revenue-to-a-record) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2014-10-30_NeoGenomics_Reports_38_increase_in_Revenue_to_a_37.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-14-396273/d775377d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-14-396273/0001193125-14-396273.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-14-396273/0001193125-14-396273-xbrl.zip \"Opens in a new window\")\n\n### Q2 2014\n\nQuarter Ended Jun 30, 2014\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/28/neogenomics-reports-record-revenues-of-20-7-million-on-40) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2014-07-17_NeoGenomics_Reports_Record_Revenues_of_20_7_28.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-14-283729/d726448d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-14-283729/0001193125-14-283729.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-14-283729/0001193125-14-283729-xbrl.zip \"Opens in a new window\")\n\n### Q1 2014\n\nQuarter Ended Mar 31, 2014\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/23/neogenomics-reports-revenue-of-18-2-million-and-adjusted) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2014-04-23_NeoGenomics_Reports_Revenue_of_18_2_Million_and_23.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-14-193896/d699144d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-14-193896/0001193125-14-193896.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-14-193896/0001193125-14-193896-xbrl.zip \"Opens in a new window\")\n\n## 2013\n\n### FY 2013\n\nFiscal Year Ended Dec 31, 2013\n\nAnnual Report [ ![Year End Results](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2971/annual_report_resized.jpg) ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2971/annual_report/NeoGenomics_2013_Annual_Report.pdf \"Opens in a new window\")\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/20/neogenomics-reports-record-revenue-of-18-3-million) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2014-02-19_NeoGenomics_Reports_Record_Revenue_of_18_3_20.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001193125-14-064714/d647097d10k.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-14-064714/0001193125-14-064714.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-14-064714/0001193125-14-064714-xbrl.zip \"Opens in a new window\")\n\n[ Annual Report PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2971/annual_report/NeoGenomics_2013_Annual_Report.pdf \"Opens in a new window\")\n\n### Q3 2013\n\nQuarter Ended Sep 30, 2013\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/16/neogenomics-reports-record-revenue-of-16-9-million) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2013-10-23_NeoGenomics_Reports_Record_Revenue_of_16_9_16.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-13-417340/d594594d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-13-417340/0001193125-13-417340.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-13-417340/0001193125-13-417340-xbrl.zip \"Opens in a new window\")\n\n### Q2 2013\n\nQuarter Ended Jun 30, 2013\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/5/neogenomics-reports-revenue-of-15-6-million-adjusted) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2013-07-31_NeoGenomics_Reports_Revenue_of_15_6_Million_5.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-13-316554/d542652d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-13-316554/0001193125-13-316554.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-13-316554/0001193125-13-316554-xbrl.zip \"Opens in a new window\")\n\n### Q1 2013\n\nQuarter Ended Mar 31, 2013\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/10/neogenomics-reports-record-quarterly-revenue-of-15-7) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2013-04-25_NeoGenomics_Reports_Record_Quarterly_Revenue_of_10.pdf \"Opens in a new window\")\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-13-214728/d508563d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-13-214728/0001193125-13-214728.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-13-214728/0001193125-13-214728-xbrl.zip \"Opens in a new window\")\n\n## 2012\n\n### FY 2012\n\nFiscal Year Ended Dec 31, 2012\n\nAnnual Report [ ![Year End Results](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2967/annual_report_resized.jpg) ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2967/annual_report/NeoGenomics_2012_Annual_Report_and_10-K.pdf \"Opens in a new window\")\n\n[ Earnings Release HTML ](https://ir.neogenomics.com/news-events/press-releases/detail/11/neogenomics-reports-181-increase-in-adjusted-ebitda-on-38) [PDF](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/news/2013-02-14_NeoGenomics_Reports_181_Increase_in_Adjusted_11.pdf \"Opens in a new window\")\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001193125-13-068680/d444070d10k.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-13-068680/0001193125-13-068680.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-13-068680/0001193125-13-068680-xbrl.zip \"Opens in a new window\")\n\n[ Annual Report PDF ](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/db/449/2967/annual_report/NeoGenomics_2012_Annual_Report_and_10-K.pdf \"Opens in a new window\")\n\n### Q3 2012\n\nQuarter Ended Sep 30, 2012\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-12-451638/d398503d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-12-451638/0001193125-12-451638.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-12-451638/0001193125-12-451638-xbrl.zip \"Opens in a new window\")\n\n### Q2 2012\n\nQuarter Ended Jun 30, 2012\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-12-337429/d351735d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-12-337429/0001193125-12-337429.pdf \"Opens in a new window\")\n\n[ 10-Q/A HTML ](/sec-filings/all-sec-filings/content/0001193125-12-357172/d351735d10qa.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-12-357172/0001193125-12-357172.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-12-357172/0001193125-12-357172-xbrl.zip \"Opens in a new window\")\n\n### Q1 2012\n\nQuarter Ended Mar 31, 2012\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-12-229834/d332643d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-12-229834/0001193125-12-229834.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-12-229834/0001193125-12-229834-xbrl.zip \"Opens in a new window\")\n\n## 2011\n\n### FY 2011\n\nFiscal Year Ended Dec 31, 2011\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001193125-12-109860/d262716d10k.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-12-109860/0001193125-12-109860.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-12-109860/0001193125-12-109860-xbrl.zip \"Opens in a new window\")\n\n### Q3 2011\n\nQuarter Ended Sep 30, 2011\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-11-280085/d224612d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-11-280085/0001193125-11-280085.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-11-280085/0001193125-11-280085-xbrl.zip \"Opens in a new window\")\n\n### Q2 2011\n\nQuarter Ended Jun 30, 2011\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-11-197538/d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-11-197538/0001193125-11-197538.pdf \"Opens in a new window\")\n\n[ 10-Q/A HTML ](/sec-filings/all-sec-filings/content/0001193125-11-204366/d10qa.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-11-204366/0001193125-11-204366.pdf \"Opens in a new window\")\n\n[ XBRL ZIP ](/sec-filings/all-sec-filings/content/0001193125-11-204366/0001193125-11-204366-xbrl.zip \"Opens in a new window\")\n\n### Q1 2011\n\nQuarter Ended Mar 31, 2011\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001193125-11-121941/d10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001193125-11-121941/0001193125-11-121941.pdf \"Opens in a new window\")\n\n## 2010\n\n### FY 2010\n\nFiscal Year Ended Dec 31, 2010\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001144204-11-010464/v212234_10k.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-11-010464/0001144204-11-010464.pdf \"Opens in a new window\")\n\n### Q3 2010\n\nQuarter Ended Sep 30, 2010\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001144204-10-056365/v200428_10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-10-056365/0001144204-10-056365.pdf \"Opens in a new window\")\n\n### Q2 2010\n\nQuarter Ended Jun 30, 2010\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001144204-10-044466/v192084_10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-10-044466/0001144204-10-044466.pdf \"Opens in a new window\")\n\n[ 10-Q/A HTML ](/sec-filings/all-sec-filings/content/0001144204-11-009615/v204453_10qa.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-11-009615/0001144204-11-009615.pdf \"Opens in a new window\")\n\n### Q1 2010\n\nQuarter Ended Mar 31, 2010\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001144204-10-024218/v182637_10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-10-024218/0001144204-10-024218.pdf \"Opens in a new window\")\n\n## 2009\n\n### FY 2009\n\nFiscal Year Ended Dec 31, 2009\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001144204-10-016236/v178787_10k.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-10-016236/0001144204-10-016236.pdf \"Opens in a new window\")\n\n### Q3 2009\n\nQuarter Ended Sep 30, 2009\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0000950123-09-065201/g21280e10vq.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0000950123-09-065201/0000950123-09-065201.pdf \"Opens in a new window\")\n\n### Q2 2009\n\nQuarter Ended Jun 30, 2009\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001144204-09-041359/v156802_10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-09-041359/0001144204-09-041359.pdf \"Opens in a new window\")\n\n### Q1 2009\n\nQuarter Ended Mar 31, 2009\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001144204-09-026369/v149189_10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-09-026369/0001144204-09-026369.pdf \"Opens in a new window\")\n\n## 2008\n\n### FY 2008\n\nFiscal Year Ended Dec 31, 2008\n\n[ 10-K HTML ](/sec-filings/all-sec-filings/content/0001144204-09-020406/v145981_10k.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-09-020406/0001144204-09-020406.pdf \"Opens in a new window\")\n\n### Q3 2008\n\nQuarter Ended Sep 30, 2008\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001144204-08-061936/v131065_10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-08-061936/0001144204-08-061936.pdf \"Opens in a new window\")\n\n### Q2 2008\n\nQuarter Ended Jun 30, 2008\n\n[ 10-Q HTML ](/sec-filings/all-sec-filings/content/0001144204-08-047059/v123238_10q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001144204-08-047059/0001144204-08-047059.pdf \"Opens in a new window\")\n\n### Q1 2008\n\nQuarter Ended Mar 31, 2008\n\n## 2007\n\n### FY 2007\n\nFiscal Year Ended Dec 31, 2007\n\n### Q3 2007\n\nQuarter Ended Sep 30, 2007\n\n### Q2 2007\n\nQuarter Ended Jun 30, 2007\n\n### Q1 2007\n\nQuarter Ended Mar 31, 2007\n\n## 2006\n\n### FY 2006\n\nFiscal Year Ended Dec 31, 2006\n\n[ 10KSB HTML ](/sec-filings/all-sec-filings/content/0001108017-07-000231/neogenomics10ksb2006.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001108017-07-000231/0001108017-07-000231.pdf \"Opens in a new window\")\n\n### Q3 2006\n\nQuarter Ended Sep 30, 2006\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-06-000109/neo10qsb093006.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-06-000109/0001070876-06-000109.pdf \"Opens in a new window\")\n\n### Q2 2006\n\nQuarter Ended Jun 30, 2006\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-06-000091/neo10qsb063006.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-06-000091/0001070876-06-000091.pdf \"Opens in a new window\")\n\n### Q1 2006\n\nQuarter Ended Mar 31, 2006\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001108017-06-000348/neo10qsb033106.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001108017-06-000348/0001108017-06-000348.pdf \"Opens in a new window\")\n\n## 2005\n\n### FY 2005\n\nFiscal Year Ended Dec 31, 2005\n\n[ 10KSB HTML ](/sec-filings/all-sec-filings/content/0001070876-06-000068/neo10k123105.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-06-000068/0001070876-06-000068.pdf \"Opens in a new window\")\n\n### Q3 2005\n\nQuarter Ended Sep 30, 2005\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-05-000110/neo10qsb093005.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-05-000110/0001070876-05-000110.pdf \"Opens in a new window\")\n\n### Q2 2005\n\nQuarter Ended Jun 30, 2005\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-05-000097/neo10qsb063005.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-05-000097/0001070876-05-000097.pdf \"Opens in a new window\")\n\n### Q1 2005\n\nQuarter Ended Mar 31, 2005\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-05-000055/neo10qsb033105.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-05-000055/0001070876-05-000055.pdf \"Opens in a new window\")\n\n## 2004\n\n### FY 2004\n\nFiscal Year Ended Dec 31, 2004\n\n[ 10KSB HTML ](/sec-filings/all-sec-filings/content/0001070876-05-000051/neo10ksb123104.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-05-000051/0001070876-05-000051.pdf \"Opens in a new window\")\n\n### Q3 2004\n\nQuarter Ended Sep 30, 2004\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-04-000167/neo10qsb112004.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-04-000167/0001070876-04-000167.pdf \"Opens in a new window\")\n\n### Q2 2004\n\nQuarter Ended Jun 30, 2004\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-04-000076/neo10qsb063004.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-04-000076/0001070876-04-000076.pdf \"Opens in a new window\")\n\n### Q1 2004\n\nQuarter Ended Mar 31, 2004\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-04-000049/neo10qsb033104.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-04-000049/0001070876-04-000049.pdf \"Opens in a new window\")\n\n## 2003\n\n### FY 2003\n\nFiscal Year Ended Dec 31, 2003\n\n[ 10KSB HTML ](/sec-filings/all-sec-filings/content/0001070876-04-000017/neo10ksb123103.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-04-000017/0001070876-04-000017.pdf \"Opens in a new window\")\n\n### Q3 2003\n\nQuarter Ended Sep 30, 2003\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-03-000151/neo10qsb093003.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-03-000151/0001070876-03-000151.pdf \"Opens in a new window\")\n\n### Q2 2003\n\nQuarter Ended Jun 30, 2003\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-03-000118/neo10qsb063003.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-03-000118/0001070876-03-000118.pdf \"Opens in a new window\")\n\n### Q1 2003\n\nQuarter Ended Mar 31, 2003\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-03-000088/neo10qsb033103.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-03-000088/0001070876-03-000088.pdf \"Opens in a new window\")\n\n## 2002\n\n### FY 2002\n\nFiscal Year Ended Dec 31, 2002\n\n[ 10KSB HTML ](/sec-filings/all-sec-filings/content/0001234034-03-000002/doc1.txt \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001234034-03-000002/0001234034-03-000002.pdf \"Opens in a new window\")\n\n### Q3 2002\n\nQuarter Ended Sep 30, 2002\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-02-000106/neo10qsbsept2002.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-02-000106/0001070876-02-000106.pdf \"Opens in a new window\")\n\n### Q2 2002\n\nQuarter Ended Jun 30, 2002\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-02-000069/neo10qsbjune2002.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-02-000069/0001070876-02-000069.pdf \"Opens in a new window\")\n\n### Q1 2002\n\nQuarter Ended Mar 31, 2002\n\n[ 10QSB HTML ](/sec-filings/all-sec-filings/content/0001070876-02-000046/neogenomicsmarch200210q.htm \"Opens in a new window\") [PDF](/sec-filings/all-sec-filings/content/0001070876-02-000046/0001070876-02-000046.pdf \"Opens in a new window\")\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "Income Statement",
          "url": "https://ir.neogenomics.com/financial-information/income-statement",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Income Statement\n\nInvestor Relations Financial Information Income Statement\n\nv3.24.3 **CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands** | 3 Months Ended | 9 Months Ended  \n---|---|---  \nSep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023  \nTotal net revenue | $ 167,824  | $ 151,954  | $ 488,566  | $ 436,091   \nCOST OF REVENUE | 92,944  | 89,643  | 275,723  | 259,075   \nGROSS PROFIT | 74,880  | 62,311  | 212,843  | 177,016   \n**Operating expenses:**  \nGeneral and administrative | 66,969  | 61,486  | 196,094  | 183,343   \nResearch and development | 7,684  | 5,285  | 23,190  | 20,182   \nSales and marketing | 20,415  | 17,610  | 62,313  | 52,770   \nRestructuring charges | 1,009  | 2,125  | 4,951  | 9,883   \nTotal operating expenses | 96,077  | 86,506  | 286,548  | 266,178   \nLOSS FROM OPERATIONS | (21,197)  | (24,195)  | (73,705)  | (89,162)   \nInterest income | (4,673)  | (4,525)  | (14,099)  | (12,057)   \nInterest expense | 1,642  | 1,685  | 4,993  | 5,226   \nOther (income) expense, net | (317)  | 96  | (52)  | (520)   \nLoss before taxes | (17,849)  | (21,451)  | (64,547)  | (81,811)   \nIncome tax benefit | (150)  | (2,935)  | (1,145)  | (8,169)   \nNET LOSS | $ (17,699)  | $ (18,516)  | $ (63,402)  | $ (73,642)   \n**NET LOSS PER SHARE**  \nBasic (in dollars per share) | $ (0.14)  | $ (0.15)  | $ (0.50)  | $ (0.59)   \nDiluted (in dollars per share) | $ (0.14)  | $ (0.15)  | $ (0.50)  | $ (0.59)   \n**WEIGHTED AVERAGE COMMON SHARES OUTSTANDING**  \nBasic (in shares) | 126,953  | 125,687  | 126,491  | 125,358   \nDiluted (in shares) | 126,953  | 125,687  | 126,491  | 125,358   \nClinical Services  \nTotal net revenue | $ 145,783  | $ 127,553  | $ 421,706  | $ 365,578   \nCOST OF REVENUE | 80,058  | 73,994  | 234,996  | 213,032   \nGROSS PROFIT | 65,725  | 53,559  | 186,710  | 152,546   \nAdvanced Diagnostics  \nTotal net revenue | 22,041  | 24,401  | 66,860  | 70,513   \nCOST OF REVENUE | 12,886  | 15,649  | 40,727  | 46,043   \nGROSS PROFIT | $ 9,155  | $ 8,752  | $ 26,133  | $ 24,470   \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_CostOfGoodsAndServicesSold  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_EarningsPerShareAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_GeneralAndAdministrativeExpense  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_GrossProfit  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncomeLossFromContinuingOperationsPerBasicShare  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | dtr-types:perShareItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | dtr-types:perShareItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncomeTaxExpenseBenefit  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of interest expense classified as nonoperating. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_InterestExpenseNonoperating  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_InvestmentIncomeInterest  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_NetIncomeLoss  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. [+ References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OperatingExpenses  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OperatingExpensesAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The net result for the period of deducting operating expenses from operating revenues. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OperatingIncomeLoss  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of income (expense) related to nonoperating activities, classified as other. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OtherNonoperatingIncomeExpense  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_ResearchAndDevelopmentExpense  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_RestructuringCostsAndAssetImpairmentCharges  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The aggregate total amount of expenses directly related to the marketing or selling of products or services. [+ References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_SellingAndMarketingExpense  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:sharesItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_WeightedAverageNumberOfSharesOutstandingBasic  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:sharesItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Details](javascript:void\\(0\\);) | **Name:** | us-gaap_StatementBusinessSegmentsAxis=neo_ClinicalServicesMember  \n---|---  \n**Namespace Prefix:**  \n**Data Type:** | na  \n**Balance Type:**  \n**Period Type:**  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Details](javascript:void\\(0\\);) | **Name:** | us-gaap_StatementBusinessSegmentsAxis=neo_AdvancedDiagnosticsMember  \n---|---  \n**Namespace Prefix:**  \n**Data Type:** | na  \n**Balance Type:**  \n**Period Type:**  \n  \n## Source\n\n[10-Q](/sec-filings/all-sec-filings/content/0001077183-24-000157/neo-20240930.htm \"View HTML of 10-Q\")\n\n[ HTML ](/sec-filings/all-sec-filings/content/0001077183-24-000157/neo-20240930.htm \"View HTML of 10-Q\") [ PDF ](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157.pdf \"View PDF of 10-Q\")\n\n[XBRL](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157-xbrl.zip \"Download Raw XBRL Files for 10-Q\")\n\n[ ZIP ](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157-xbrl.zip \"Download Raw XBRL Files for 10-Q\")\n\nPublished: November 5, 2024 \n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "Balance Sheet",
          "url": "https://ir.neogenomics.com/financial-information/balance-sheet",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Balance Sheet\n\nInvestor Relations Financial Information Balance Sheet\n\nv3.24.3 **CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands** | Sep. 30, 2024 | Dec. 31, 2023  \n---|---|---  \n**Current assets**  \nCash and cash equivalents | $ 361,992  | $ 342,488   \nMarketable securities, at fair value | 25,821  | 72,715   \nAccounts receivable, net | 151,428  | 131,227   \nInventories | 24,457  | 24,156   \nPrepaid assets | 18,235  | 17,987   \nOther current assets | 8,308  | 8,239   \nTotal current assets | 590,241  | 596,812   \nProperty and equipment (net of accumulated depreciation of $181,340 and $158,211, respectively) | 93,038  | 92,012   \nOperating lease right-of-use assets | 81,442  | 91,769   \nIntangible assets, net | 348,042  | 373,128   \nGoodwill | 522,766  | 522,766   \nOther assets | 5,582  | 4,742   \nTotal non-current assets | 1,050,870  | 1,084,417   \nTotal assets | 1,641,111  | 1,681,229   \n**Current liabilities**  \nAccounts payable | 16,514  | 20,334   \nAccrued compensation | 52,165  | 53,161   \nAccrued expenses and other liabilities | 22,998  | 15,069   \nCurrent portion of operating lease liabilities | 3,716  | 5,610   \nCurrent portion of convertible senior notes, net | 200,424  | 0   \nContract liabilities | 589  | 2,130   \nTotal current liabilities | 296,406  | 96,304   \n**Long-term liabilities**  \nOperating lease liabilities | 62,172  | 67,871   \nConvertible senior notes, net | 339,956  | 538,198   \nDeferred income tax liabilities, net | 22,771  | 24,285   \nOther long-term liabilities | 11,596  | 13,034   \nTotal long-term liabilities | 436,495  | 643,388   \nTotal liabilities | 732,901  | 739,692   \nCommitments and contingencies (Note 11)  \n**Stockholders’ equity**  \nCommon stock, $0.001 par value, (250,000,000 shares authorized; 128,061,944 and 127,369,142 shares issued and outstanding, respectively) | 128  | 127   \nAdditional paid-in capital | 1,219,182  | 1,190,139   \nAccumulated other comprehensive loss | (643)  | (1,674)   \nAccumulated deficit | (310,457)  | (247,055)   \nTotal stockholders’ equity | 908,210  | 941,537   \nTotal liabilities and stockholders’ equity | $ 1,641,111  | $ 1,681,229   \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AccountsPayableCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AccountsReceivableNetCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. [+ References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AccruedLiabilitiesAndOtherLiabilities  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AdditionalPaidInCapitalCommonStock  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of asset recognized for present right to economic benefit. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_Assets  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of asset recognized for present right to economic benefit, classified as current. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AssetsCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AssetsCurrentAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AssetsNoncurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_CashAndCashEquivalentsAtCarryingValue  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_CommitmentsAndContingencies  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_CommonStockValueOutstanding  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_ContractWithCustomerLiabilityCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_ConvertibleDebtNoncurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_ConvertibleNotesPayableCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_DeferredIncomeTaxLiabilitiesNet  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_EmployeeRelatedLiabilitiesCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_Goodwill  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IntangibleAssetsNetExcludingGoodwill  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_InventoryNet  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_Liabilities  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_LiabilitiesAndStockholdersEquity  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_LiabilitiesCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_LiabilitiesCurrentAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of obligation due after one year or beyond the normal operating cycle, if longer. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_LiabilitiesNoncurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_LiabilitiesNoncurrentAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OperatingLeaseLiabilityCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OperatingLeaseLiabilityNoncurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of lessee's right to use underlying asset under operating lease. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OperatingLeaseRightOfUseAsset  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of current assets classified as other. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OtherAssetsCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of noncurrent assets classified as other. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OtherAssetsNoncurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OtherLiabilitiesNoncurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_PrepaidExpenseCurrent  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_PropertyPlantAndEquipmentNet  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of accumulated undistributed earnings (deficit). [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_RetainedEarningsAccumulatedDeficit  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_StockholdersEquity  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_StockholdersEquityAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n## Source\n\n[10-Q](/sec-filings/all-sec-filings/content/0001077183-24-000157/neo-20240930.htm \"View HTML of 10-Q\")\n\n[ HTML ](/sec-filings/all-sec-filings/content/0001077183-24-000157/neo-20240930.htm \"View HTML of 10-Q\") [ PDF ](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157.pdf \"View PDF of 10-Q\")\n\n[XBRL](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157-xbrl.zip \"Download Raw XBRL Files for 10-Q\")\n\n[ ZIP ](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157-xbrl.zip \"Download Raw XBRL Files for 10-Q\")\n\nPublished: November 5, 2024 \n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "Cash Flow",
          "url": "https://ir.neogenomics.com/financial-information/cash-flow",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.neogenomics.com) Ignore\n\n[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Cash Flow\n\nInvestor Relations Financial Information Cash Flow\n\nv3.24.3 **CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)** | 9 Months Ended  \n---|---  \nSep. 30, 2024 | Sep. 30, 2023  \n**CASH FLOWS FROM OPERATING ACTIVITIES**  \nNet loss | $ (63,402,000)  | $ (73,642,000)   \n**Adjustments to reconcile net loss to net cash used in operating activities:**  \nDepreciation | 29,274,000  | 27,872,000   \nAmortization of intangibles | 25,085,000  | 26,350,000   \nStock-based compensation | 25,085,000  | 17,643,000   \nNon-cash operating lease expense | 7,022,000  | 6,860,000   \nAmortization of convertible debt discount | 2,041,000  | 2,015,000   \nAmortization of debt issue costs | 141,000  | 139,000   \nLoss on disposal of assets, net | 63,000  | 334,000   \nImpairment of assets | 333,000  | 1,703,000   \nOther adjustments | 141,000  | 122,000   \n**Changes in assets and liabilities, net**  \nAccounts receivable, net | (20,201,000)  | (12,928,000)   \nInventories | (408,000)  | (252,000)   \nPrepaid and other assets | (1,206,000)  | (5,165,000)   \nOperating lease liabilities | (4,287,000)  | (5,871,000)   \nDeferred income tax liabilities, net | (1,514,000)  | (9,380,000)   \nAccrued compensation | (996,000)  | 7,453,000   \nAccounts payable and other liabilities | 52,000  | (2,990,000)   \nNet cash used in operating activities | (2,777,000)  | (19,737,000)   \n**CASH FLOWS FROM INVESTING ACTIVITIES**  \nPurchases of marketable securities | 0  | (6,756,000)   \nProceeds from maturities of marketable securities | 47,784,000  | 87,963,000   \nPurchases of property and equipment | (29,462,000)  | (21,695,000)   \nNet cash provided by investing activities | 18,322,000  | 59,512,000   \n**CASH FLOWS FROM FINANCING ACTIVITIES**  \nRepayment of equipment financing obligations | 0  | (66,000)   \nIssuance of common stock, net | 3,959,000  | 3,350,000   \nNet cash provided by financing activities | 3,959,000  | 3,284,000   \nNet change in cash and cash equivalents | 19,504,000  | 43,059,000   \nCash and cash equivalents, beginning of period | 342,488,000  | 263,180,000   \nCash and cash equivalents, end of period | 361,992,000  | 306,239,000   \n**Supplemental disclosure of cash flow information:**  \nInterest paid | 2,139,000  | 2,121,000   \nIncome taxes paid, net | 319,000  | 175,000   \n**Supplemental disclosure of non-cash investing and financing information:**  \nPurchases of property and equipment included in accounts payable | $ 1,688,000  | $ 636,000   \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Repayments of Equipment and Other Finance Obligation [+ References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | neo_RepaymentsOfEquipmentAndOtherFinanceObligation  \n---|---  \n**Namespace Prefix:** | neo_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AmortizationOfDebtDiscountPremium  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of amortization expense attributable to debt issuance costs. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AmortizationOfFinancingCosts  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_AmortizationOfIntangibleAssets  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Future cash outflow to pay for purchases of fixed assets that have occurred. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_CapitalExpendituresIncurredButNotYetPaid  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | instant  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_Depreciation  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_GainLossOnDispositionOfAssets1  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_ImpairmentOfLongLivedAssetsHeldForUse  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncomeTaxesPaidNet  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncreaseDecreaseInAccountsReceivable  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncreaseDecreaseInAccruedLiabilities  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncreaseDecreaseInDeferredIncomeTaxes  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncreaseDecreaseInInventories  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncreaseDecreaseInOperatingCapitalAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of increase (decrease) in obligation for operating lease. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncreaseDecreaseInOperatingLeaseLiability  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of increase (decrease) in prepaid expenses, and assets classified as other. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_InterestPaidNet  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_NetCashProvidedByUsedInFinancingActivities  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_NetCashProvidedByUsedInInvestingActivities  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_NetCashProvidedByUsedInOperatingActivities  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_NetIncomeLoss  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of operating lease expense. Excludes sublease income. [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OperatingLeaseExpense  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). [+ References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_OtherOperatingActivitiesCashFlowStatement  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_PaymentsToAcquirePropertyPlantAndEquipment  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | credit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)The cash inflow from the additional capital contribution to the entity. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_ProceedsFromIssuanceOfCommonStock  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). [+ References](javascript:void\\(0\\);)Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- Definition](javascript:void\\(0\\);)Amount of noncash expense for share-based payment arrangement. [+ References](javascript:void\\(0\\);)Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_ShareBasedCompensation  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:monetaryItemType  \n**Balance Type:** | debit  \n**Period Type:** | duration  \n  \n[X](javascript:void\\(0\\);)  \n---  \n[- References](javascript:void\\(0\\);)No definition available. [+ Details](javascript:void\\(0\\);) | **Name:** | us-gaap_SupplementalCashFlowInformationAbstract  \n---|---  \n**Namespace Prefix:** | us-gaap_  \n**Data Type:** | xbrli:stringItemType  \n**Balance Type:** | na  \n**Period Type:** | duration  \n  \n## Source\n\n[10-Q](/sec-filings/all-sec-filings/content/0001077183-24-000157/neo-20240930.htm \"View HTML of 10-Q\")\n\n[ HTML ](/sec-filings/all-sec-filings/content/0001077183-24-000157/neo-20240930.htm \"View HTML of 10-Q\") [ PDF ](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157.pdf \"View PDF of 10-Q\")\n\n[XBRL](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157-xbrl.zip \"Download Raw XBRL Files for 10-Q\")\n\n[ ZIP ](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157-xbrl.zip \"Download Raw XBRL Files for 10-Q\")\n\nPublished: November 5, 2024 \n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "All SEC Filings",
          "url": "https://ir.neogenomics.com/sec-filings/all-sec-filings",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# All SEC Filings\n\nInvestor Relations SEC Filings All SEC Filings\n\nFiling Type: View All 10-K 10-K/A 10-Q 10-Q/A 10KSB 10KSB/A 10QSB 144 3 3/A 4 4/A 424B3 424B5 424B7 424B8 5 8-A12B 8-A12G 8-K 8-K/A ARS AW CERTNAS CORRESP CT ORDER D DEF 14A DEFA14A DEFM14A DEFR14A EFFECT FWP NT 10-K NT 10-Q POS AM PRE 14A PREM14A REGDEX REGDEX/A RW S-1 S-1/A S-3 S-3ASR S-8 SB-2 SB-2/A SC 13D SC 13D/A SC 13G SC 13G/A UPLOAD\n\nYear: View All 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999\n\nDate | Form | Description | XBRL | Pages  \n---|---|---|---|---  \n11/19/24 |  4  |  [Form 4: Statement of changes in beneficial ownership of securities](/sec-filings/all-sec-filings/content/0001077183-24-000162/wk-form4_1732056189.html \"Opens in a new window\") | 2  \n11/15/24 |  144  |  [Form 144: Filing for proposed sale of securities under Rule 144](/sec-filings/all-sec-filings/content/0001950047-24-008633/primary_doc.html \"Opens in a new window\") | 2  \n11/14/24 |  SC 13G/A  |  [Form SC 13G/A: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions](/sec-filings/all-sec-filings/content/0001897612-24-001911/neo13gasep24.txt \"Opens in a new window\") | 2  \n11/14/24 |  SC 13G  |  [Form SC 13G: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions](/sec-filings/all-sec-filings/content/0001274173-24-000100/Neogenomics093024.txt \"Opens in a new window\") | 3  \n11/05/24 |  4  |  [Form 4: Statement of changes in beneficial ownership of securities](/sec-filings/all-sec-filings/content/0001077183-24-000159/wk-form4_1730841106.html \"Opens in a new window\") | 1  \n  \n[ rss_feed Filing RSS ](https://ir.neogenomics.com/sec-filings/all-sec-filings/rss \"Opens in a new window\")\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "Annual Reports",
          "url": "https://ir.neogenomics.com/sec-filings/annual-reports",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.neogenomics.com) Ignore\n\n[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Annual Reports\n\nInvestor Relations SEC Filings Annual Reports\n\nFiling Type: View All 10-K 10-K/A 10KSB 10KSB/A ARS NT 10-K\n\nYear: View All 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999\n\nDate | Form | Description | XBRL | Pages  \n---|---|---|---|---  \n04/08/24 |  ARS  |  [Form ARS: Annual report to security holders](/sec-filings/all-sec-filings/content/0001140361-24-018616/0001140361-24-018616.pdf \"Opens in a new window\") | 112  \n02/20/24 |  10-K  |  [Form 10-K: Annual report pursuant to Section 13 and 15(d)](/sec-filings/all-sec-filings/content/0001077183-24-000011/neo-20231231.htm \"Opens in a new window\") | 106  \n04/07/23 |  ARS  |  [Form ARS: Annual report to security holders](/sec-filings/all-sec-filings/content/0001193125-23-095212/0001193125-23-095212.pdf \"Opens in a new window\") | 140  \n02/24/23 |  10-K  |  [Form 10-K: Annual report pursuant to Section 13 and 15(d)](/sec-filings/all-sec-filings/content/0001077183-23-000023/neo-20221231.htm \"Opens in a new window\") |  [ ![](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/images/icon-XBRL.svg) ](/sec-filings/all-sec-filings/content/0001077183-23-000023/0001077183-23-000023-xbrl.zip \"Download Raw XBRL Files\") | 142  \n02/25/22 |  10-K  |  [Form 10-K: Annual report pursuant to Section 13 and 15(d)](/sec-filings/all-sec-filings/content/0001077183-22-000017/neo-20211231.htm \"Opens in a new window\") |  [ ![](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/images/icon-XBRL.svg) ](/sec-filings/all-sec-filings/content/0001077183-22-000017/0001077183-22-000017-xbrl.zip \"Download Raw XBRL Files\") | 117  \n  \n[ rss_feed Filing RSS ](https://ir.neogenomics.com/sec-filings/annual-reports/rss \"Opens in a new window\")\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "Quarterly Reports",
          "url": "https://ir.neogenomics.com/sec-filings/quarterly-reports",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.neogenomics.com) Ignore\n\n[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Quarterly Reports\n\nInvestor Relations SEC Filings Quarterly Reports\n\nFiling Type: View All 10-Q 10-Q/A 10QSB NT 10-Q\n\nYear: View All 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999\n\nDate | Form | Description | XBRL | Pages  \n---|---|---|---|---  \n11/05/24 |  10-Q  |  [Form 10-Q: Quarterly report pursuant to Section 13 or 15(d)](/sec-filings/all-sec-filings/content/0001077183-24-000157/neo-20240930.htm \"Opens in a new window\") |  [ ![](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/images/icon-XBRL.svg) ](/sec-filings/all-sec-filings/content/0001077183-24-000157/0001077183-24-000157-xbrl.zip \"Download Raw XBRL Files\") | 55  \n07/30/24 |  10-Q  |  [Form 10-Q: Quarterly report pursuant to Section 13 or 15(d)](/sec-filings/all-sec-filings/content/0001077183-24-000109/neo-20240630.htm \"Opens in a new window\") |  [ ![](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/images/icon-XBRL.svg) ](/sec-filings/all-sec-filings/content/0001077183-24-000109/0001077183-24-000109-xbrl.zip \"Download Raw XBRL Files\") | 42  \n04/30/24 |  10-Q  |  [Form 10-Q: Quarterly report pursuant to Section 13 or 15(d)](/sec-filings/all-sec-filings/content/0001077183-24-000054/neo-20240331.htm \"Opens in a new window\") |  [ ![](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/images/icon-XBRL.svg) ](/sec-filings/all-sec-filings/content/0001077183-24-000054/0001077183-24-000054-xbrl.zip \"Download Raw XBRL Files\") | 46  \n11/06/23 |  10-Q  |  [Form 10-Q: Quarterly report pursuant to Section 13 or 15(d)](/sec-filings/all-sec-filings/content/0001077183-23-000138/neo-20230930.htm \"Opens in a new window\") | 44  \n08/08/23 |  10-Q  |  [Form 10-Q: Quarterly report pursuant to Section 13 or 15(d)](/sec-filings/all-sec-filings/content/0001077183-23-000103/neo-20230630.htm \"Opens in a new window\") |  [ ![](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/images/icon-XBRL.svg) ](/sec-filings/all-sec-filings/content/0001077183-23-000103/0001077183-23-000103-xbrl.zip \"Download Raw XBRL Files\") | 42  \n  \n[ rss_feed Filing RSS ](https://ir.neogenomics.com/sec-filings/quarterly-reports/rss \"Opens in a new window\")\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        },
        {
          "title": "Section 16 Filings",
          "url": "https://ir.neogenomics.com/sec-filings/section-16-filings",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.neogenomics.com) Ignore\n\n[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#footer)\n\n[ ![Home](https://d1io3yog0oux5.cloudfront.net/_dc2d9666cc5d27e2ee1be53110c63e18/neogenomics/files/theme/site-files/20240305/neogenomics.com/themes/custom/neogenomics/assets/images/logo-white.png) ](https://neogenomics.com)\n\n[ 866.776.5907](tel:8667765907)\n\n[ Glassdoor](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter](https://twitter.com/NeoGenomics)\n\n[ YouTube](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\n[ Mobile Nav ](#)\n\n# Section 16 Filings\n\nInvestor Relations SEC Filings Section 16 Filings\n\nFiling Type: View All 3 3/A 4 4/A 5\n\nYear: View All 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999\n\nDate | Form | Description | XBRL | Pages  \n---|---|---|---|---  \n11/19/24 |  4  |  [Form 4: Statement of changes in beneficial ownership of securities](/sec-filings/all-sec-filings/content/0001077183-24-000162/wk-form4_1732056189.html \"Opens in a new window\") | 2  \n11/05/24 |  4  |  [Form 4: Statement of changes in beneficial ownership of securities](/sec-filings/all-sec-filings/content/0001077183-24-000159/wk-form4_1730841106.html \"Opens in a new window\") | 1  \n11/05/24 |  3  |  [Form 3: Initial statement of beneficial ownership of securities](/sec-filings/all-sec-filings/content/0001077183-24-000158/wk-form3_1730841030.html \"Opens in a new window\") | 5  \n09/04/24 |  4  |  [Form 4: Statement of changes in beneficial ownership of securities](/sec-filings/all-sec-filings/content/0001077183-24-000146/wk-form4_1725480484.html \"Opens in a new window\") | 2  \n08/19/24 |  4  |  [Form 4: Statement of changes in beneficial ownership of securities](/sec-filings/all-sec-filings/content/0001077183-24-000143/wk-form4_1724098745.html \"Opens in a new window\") | 1  \n  \n[ rss_feed Filing RSS ](https://ir.neogenomics.com/sec-filings/section-16-filings/rss \"Opens in a new window\")\n\n  * [Accessibility statement](/accessibility-statement)\n  * [Email alerts](/news-events/email-alerts)\n  * [Company profile](/company-information)\n  * [RSS news feed](https://ir.neogenomics.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nSearch\n\n[ Phone number](tel:8667765907)\n\n[ Glassdoor Icon](https://www.glassdoor.com/Overview/Working-at-NeoGenomics-EI_IE22281.11,22.htm)\n\n[ Linkedin Icon](https://www.linkedin.com/company/neogenomics-laboratories/mycompany/)\n\n[ Twitter Icon](https://twitter.com/NeoGenomics)\n\n[ YouTube Icon](https://www.youtube.com/channel/UCBa0vLyn1ZO7tW-RyJOrxPA)\n\nSearch\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\n[Manage cookie settings...](#)\n\nI decline optional cookiesI accept all cookies\n"
        }
      ]
    }
  ]
}